real-time news and commentary for investors
Monday, Aug 19
Johnson & Johnson complete acquisition of Aragon Pharmaceuticals
- Johnson & Johnson (JNJ) says it's completed its acquisition of Aragon Pharmaceuticals, a privately-held pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers.
- Development of compounds from Aragon's androgen receptor antagonist program, including its lead androgen receptor signaling inhibitor, ARN-509, will be managed by JNJ's Janssen Research & Development.